A New Frontier in Hypercortisolism Control
A recent international real-world study published in the Journal of Clinical Endocrinology & Metabolism provides significant data on the efficacy and safety of osilodrostat for treating adrenal Cushing syndrome (CS). The research evaluated 28 patients, finding that 66.7% of those treated for more than four weeks achieved a response, defined as a greater than 50% reduction in urinary free cortisol. For patients continuing therapy beyond 12 weeks, the response rate increased to 87.5%. Notably, the study identified that using osilodrostat as a non-first-line therapy after other steroidogenesis inhibitors was a strong predictor of a positive treatment response. The therapy also demonstrated a beneficial impact on key clinical parameters, leading to significant decreases in systolic blood pressure and body weight.
Study Significance: For rheumatologists managing complex inflammatory and autoimmune conditions often requiring corticosteroid therapy, this study offers critical insights into managing iatrogenic hypercortisolism. The findings on osilodrostat’s efficacy, particularly as a subsequent-line agent, can inform therapeutic strategies for patients who develop adrenal CS, a serious complication of long-term steroid use. Understanding the timeline to response and the associated improvements in cardiovascular risk factors like hypertension and weight is directly applicable to holistic patient management in rheumatologic care.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
